San Raffaele Hospital performs over 52,000 operations annually, specializing in targeted therapy for rare immune and genetic diseases. Treatment may cost around $3,200–$5,700. Dr. Fabio Ciceri, Head of Hematology and Bone Marrow Transplantation, leads cell and gene therapy trials with 180+ published papers.
San Raffaele Hospital is a top European research center with Italy's IRCCS accreditation. It achieved the world's first stem cell therapy for severe combined immune deficiency. Its main specialties are oncology, neurosurgery, and cardiovascular surgery.
Dr. Fabio Ciceri heads the Hematology and Bone Marrow Transplantation Unit at San Raffaele Research Hospital. He is a primary investigator in clinical trials for cell and gene therapies. These trials treat hematological cancers, immune deficiencies, and neuromuscular disorders. Dr. Ciceri works at San Raffaele, the hospital that achieved the world's first stem cell therapy for ADA-SCID.
San Raffaele Hospital is a top European research center with Italy's IRCCS accreditation. It achieved the world's first stem cell therapy for severe combined immune deficiency. Its main specialties are oncology, neurosurgery, and cardiovascular surgery.
This therapy focuses on specific cancer cells, curbing their growth and spread with fewer side effects.
"},"830":{"operation":{"name":"Lutetium-177 therapy","alias":"lutetium-177-therapy","use_for_listing":true},"country_price":{"US":{"amount":42000,"max_amount":54000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"TR":{"amount":6500,"max_amount":9000,"currency":"USD","clinic_count":9,"price_kind":"from_range","price_source":"tariff","scope":"country"},"TH":{"amount":7000,"max_amount":9500,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"AT":{"amount":18000,"max_amount":30000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"IT":{"amount":9500,"max_amount":14500,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"}},"available_clinics":{"US":false,"TR":true,"TH":false,"AT":false,"IT":false},"description":"This therapy uses radioactive particles to kill cancer cells, offering precise, effective treatment with fewer side effects.
"},"1553":{"operation":{"name":"Oncothermia","alias":"oncothermia","use_for_listing":false},"country_price":{"US":{"amount":6000,"max_amount":14000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"TR":{"amount":2400,"max_amount":5000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"TH":{"amount":1800,"max_amount":3200,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"AT":{"amount":2400,"max_amount":4600,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"IT":{"amount":3600,"max_amount":6000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"}},"available_clinics":{"US":false,"TR":false,"TH":true,"AT":false,"IT":false}},"1653":{"operation":{"name":"Actinium-225 Therapy","alias":"actinium-225-therapy","use_for_listing":true},"country_price":{"US":{"amount":60000,"max_amount":110000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"TR":{"amount":9000,"max_amount":16000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"TH":{"amount":24000,"max_amount":38000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"AT":{"amount":12500,"max_amount":21000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"},"IT":{"amount":18000,"max_amount":30000,"currency":"USD","clinic_count":0,"price_kind":"estimate","price_source":"parsed","scope":"country"}},"available_clinics":{"US":false,"TR":true,"TH":false,"AT":false,"IT":false}}}},"operationIndicators":{"details":{"anesthesia":"local","days_in_clinic":1,"days_in_country":2,"rehabilitation_days":1,"satisfied_percent":78,"treatment_duration_hours":4},"illness_kind_details":{"requests_processed":46119}},"direction":{"id":10,"name":"Oncology","alias":"oncology"},"illness_kind":{"id":10,"name":{"en":"Oncology"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":0,"max":3,"unit":"days","qualifier":"Most patients keep working; depends on agent side effects and infusion schedule."},"complication_rate_pct":{"min":20,"max":50,"unit":"percent","qualifier":"Grade 3-4 adverse events during treatment; any-grade side effects are far more common, varying by agent."},"contraindications":["Known severe hypersensitivity to the specific agent or its components","Pregnancy and breastfeeding for many agents (agent-specific)","Severe uncontrolled liver, heart or lung dysfunction (relative, agent-dependent)","Clinically significant drug interactions with the specific agent (relative, agent-specific)"],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Typical oral or infusion-based cycles are given without overnight stay; inpatient stay is not usual for uncomplicated treatment."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity usually continues; intensity limited by fatigue, rash, diarrhea or cardiac precautions."},"final_result_months":{"min":2,"max":6,"unit":"months","qualifier":"Response is judged by imaging after several cycles; depends on tumor type and agent."},"fly_home_after_days":{"min":1,"max":3,"unit":"days","qualifier":"After first dose, oncology team usually wants early tolerance observed; depends on agent and infusion reactions."},"follow_up_visits":[{"purpose":"assessment","after":{"min":7,"max":21,"unit":"days","qualifier":"Early tolerance check with blood tests and side-effect review."},"requirement":"routine"},{"purpose":"result_review","after":{"min":56,"max":90,"unit":"days","qualifier":"First response imaging and blood markers; timing depends on agent and cancer type."},"requirement":"routine"}],"indications":["Cancers with molecular targets: HER2, EGFR, ALK, BRAF, BCR-ABL","Hematologic malignancies and solid tumors with a matched targeted agent","Some non-cancer conditions with defined molecular targets"],"main_risks":["Skin reactions such as rash and dryness","Diarrhea, nausea and other gastrointestinal effects","Liver enzyme elevation","Hypertension, cardiac effects or bleeding with certain agents","Infusion reactions with antibody-based agents","Blood count changes"],"pain":"Treatment itself is painless apart from IV cannulation. Side effects such as rash, mouth sores or joint aches are usually mild to moderate.","preparation":["Molecular target or biomarker confirmed by tissue or blood testing","Baseline blood tests and organ function assessment","Review of current medications and supplements with the oncology team","Baseline cardiac or other agent-specific assessment where required","Discussion of expected side effects and contraception where relevant"],"recovery_timeline":[{"phase":"Treatment day","description":"Oral dose started or infusion given with observation for reactions.","restrictions":["Report fever or breathing difficulty immediately","Follow agent-specific food and drug rules"]},{"phase":"First 2 weeks","description":"Early side effects such as rash, diarrhea or fatigue may appear and are managed with supportive care.","restrictions":["Avoid sun exposure","Avoid new supplements without approval"]},{"phase":"Ongoing cycles","description":"Treatment continues with periodic blood tests and imaging to assess response.","restrictions":["Contraception where relevant","Avoid grapefruit with some agents"]}],"rehabilitation_days":{"min":0,"max":3,"unit":"days","qualifier":"Ordinary activity resumes quickly; longer if infusion reactions or fatigue occur."},"result_longevity":"Response lasts as long as the drug is effective, often months to several years. Acquired resistance eventually develops in many cancers.","revision_rate_pct":null,"scars":"No incisions or scars; only minor puncture marks from IV cannulation.","sessions_or_stages":{"sessions":{"min":4,"max":13,"unit":"visits","qualifier":"Infusion-based schedule every 1-3 weeks until first imaging; oral agents need no infusion visits."},"stages":[{"code":"biomarker_confirmation","label":"Biomarker confirmation and baseline tests","after":{"min":0,"max":0,"unit":"days","qualifier":"Before first dose."}},{"code":"treatment_start","label":"First dose or infusion","after":{"min":0,"max":7,"unit":"days","qualifier":"Starts once testing is confirmed."}},{"code":"response_assessment","label":"First response imaging","after":{"min":56,"max":90,"unit":"days","qualifier":"After several cycles."}}],"qualifier":"Treatment continues until progression or intolerance; typical first-phase schedule shown."},"success":{"metric":"Objective tumor response rate at first imaging","value":60,"unit":"percent","horizon":"2-3 months","population":"Adults with biomarker-matched advanced cancer receiving a matched targeted agent","evidence_status":"limited"},"techniques":[{"name":"Small-molecule inhibitors (oral, e.g. tyrosine kinase inhibitors)","suits_whom":"Patients whose tumor carries a matching targetable alteration","recovery":"No recovery period; usually taken continuously at home with periodic monitoring."},{"name":"Monoclonal antibodies (intravenous or subcutaneous)","suits_whom":"Patients with target-expressing tumors such as HER2-positive cancers","recovery":"Given at scheduled infusion visits; usually no recovery time beyond infusion-related effects."},{"name":"Antibody-drug conjugates","suits_whom":"Selected patients with target-expressing cancers and suitable prior treatment history","recovery":"Given at scheduled infusion visits with monitoring for agent-specific toxicity."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":0.5,"max":3,"unit":"hours","qualifier":"Per infusion visit; first infusion is longest. Oral agents are taken at home."},"initial_assessment_documents":["Pathology report with tumor type and stage","Molecular or genomic testing report","Recent CT or PET-CT scans","Summary of previous cancer treatments","Recent blood test results","Oncologist's latest treatment notes (if available)"],"travel_trips":{"min":2,"max":3,"one_trip_possible":false,"qualifier":"Start visit with first dose and tolerance check, then response imaging at 2-3 months; routine monitoring at home."},"clinic_checks":null,"red_flags":null,"warning_signs":null,"take_home":null,"alternatives":null,"technique_details":null}},"hrefLanguages":[{"rel":"alternate","hreflang":"ru","language":"ru","href":"https://ru.bookimed.com/clinics/country=italiya/city=milan/procedure=targetnaya-terapiya/"}],"questionsAndAnswers":[],"seoTests":{"thin_content":false,"no_txt_after_3_clinics":false},"offerFilters":{"offer_count":0,"price_filter":{"from":0,"to":0,"avg":0}},"leadsCount":{"leads_count":8},"manualSeo":[],"updatedAt":"2026-11-05T22:48:52.000Z","activeCountries":["IT","TR","AT","TH"],"hasVideoReviewsByContext":true,"hasCriticalApiFallback":false}